Muscarinic Type 3 Receptor Induces Cytoprotective Signaling in Salivary Gland Cells through Epidermal Growth Factor Receptor Transactivation

作者: Mikihito Kajiya , Isao Ichimonji , Christine Min , Tongbo Zhu , Jun-O Jin

DOI: 10.1124/MOL.111.077354

关键词:

摘要: Muscarinic type 3 receptor (M3R) plays a pivotal role in the induction of glandular fluid secretions. Although M3R is often target autoantibodies Sjogren's syndrome (SjS), chemical agonists for are clinically used to stimulate saliva secretion patients with SjS. Aside from its activity promoting secretion, however, it unclear whether activation related other biological events This study aimed investigate cytoprotective effect agonist-mediated on apoptosis induced human salivary gland (HSG) cells. Carbachol (CCh), muscarinic receptor-specific agonist, abrogated tumor necrosis factor α/interferon γ-induced through pathways involving caspase 3/7, but was decreased by antagonist, mitogen-activated protein kinase kinase/extracellular signal-regulated (ERK) inhibitor, phosphatidylinositol 3-kinase/Akt or an epidermal growth (EGFR) inhibitor. Ligation CCh transactivated EGFR and phosphorylated ERK Akt, downstream targets EGFR. Inhibition intracellular calcium release C δ, both which involved cell signaling M3R-mediated did not affect CCh-induced Akt phosphorylation. stimulated Src phosphorylation binding A inhibitor attenuated CCh/M3R-induced transactivation cascades. Overall, these results indicated that CCh/M3R leading phosphorylation, turn suppressed 3/7-mediated apoptotic signals HSG study, first time, proposes CCh-mediated can promote only also survival cells inflammatory context

参考文章(55)
R. I. Fox, Ho-Il Kang, Pathogenesis of Sjögren's syndrome. Rheumatic Diseases Clinics of North America. ,vol. 18, pp. 517- 538 ,(1992)
Neil E Bhola, Jennifer R Grandis, Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer Frontiers in Bioscience. ,vol. 13, pp. 1857- 1865 ,(2008) , 10.2741/2805
Tetsuo Yanagawa, Hideo Yoshida, Masayuki Azuma, Mitsunobu Sato, Yoshio Hayashi, Yoshiaki Yura, Akemichi Ueno, Intermediate-sized Filaments and Specific Markers in a Human Salivary Gland Adenocarcinoma Cell Line and Its Nude Mouse Tumors Cancer Research. ,vol. 45, pp. 3878- 3890 ,(1985)
Kobi Rosenblum, Marie Futter, Matthew Jones, EC Hulme, TVP Bliss, None, ERKI/II Regulation by the Muscarinic Acetylcholine Receptors in Neurons The Journal of Neuroscience. ,vol. 20, pp. 977- 985 ,(2000) , 10.1523/JNEUROSCI.20-03-00977.2000
L S Steelman, S L Abrams, J Whelan, F E Bertrand, D E Ludwig, J Bäsecke, M Libra, F Stivala, M Milella, A Tafuri, P Lunghi, A Bonati, A M Martelli, J A McCubrey, Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia Leukemia. ,vol. 22, pp. 686- 707 ,(2008) , 10.1038/LEU.2008.26
Kristen L. Pierce, Richard T. Premont, Robert J. Lefkowitz, Seven-transmembrane receptors. Nature Reviews Molecular Cell Biology. ,vol. 3, pp. 639- 650 ,(2002) , 10.1038/NRM908
William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, Ruth C. Kempf, Stephen L. Abrams, Richard A. Franklin, Jörg Bäsecke, Franca Stivala, Marco Donia, Paolo Fagone, Graziella Malaponte, Maria C. Mazzarino, Ferdinando Nicoletti, Massimo Libra, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Piotr Laidler, Michele Milella, Agostino Tafuri, Antonio Bonati, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli, James A. McCubrey, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health Oncotarget. ,vol. 2, pp. 135- 164 ,(2011) , 10.18632/ONCOTARGET.240
Indu S. Ambudkar, Yukiharu Hiramatsu, Timothy Lockwich, Bruce J. Baum, Activation and regulation of calcium entry in rat parotid gland acinar cells. Critical Reviews in Oral Biology & Medicine. ,vol. 4, pp. 421- 425 ,(1993) , 10.1177/10454411930040032301
Enrique Rozengurt, Mitogenic signaling pathways induced by G protein‐coupled receptors Journal of Cellular Physiology. ,vol. 213, pp. 589- 602 ,(2007) , 10.1002/JCP.21246